NT PHARMA Forecasts Net Loss Between RMB 10.9 Million and RMB 15.9 Million for 2025 Fiscal Year

Stock News

Mar 30

NT PHARMA (01011) has announced that following further discussions with its auditor during the audit process and based on audit work completed to the date of this announcement, the Board wishes to further inform shareholders and potential investors that the Group expects to recognize a one-time non-cash gain of approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) related to the issuance of new shares for debt settlement. Consequently, the Group's anticipated loss for the fiscal year ending December 31, 2025, is expected to be reduced by approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) compared to the figure disclosed in the previous announcement. The revised expected net loss is now projected to be in the range of approximately RMB 10.9 million to RMB 15.9 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1152861261"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152861261\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152861261?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152861261","market":"sh","top_or_hot":-1,"title":"NT PHARMA Forecasts Net Loss Between RMB 10.9 Million and RMB 15.9 Million for 2025 Fiscal Year","media":"Stock News","content":"<p>NT PHARMA (01011) has announced that following further discussions with its auditor during the audit process and based on audit work completed to the date of this announcement, the Board wishes to further inform shareholders and potential investors that the Group expects to recognize a one-time non-cash gain of approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) related to the issuance of new shares for debt settlement. Consequently, the Group's anticipated loss for the fiscal year ending December 31, 2025, is expected to be reduced by approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) compared to the figure disclosed in the previous announcement. The revised expected net loss is now projected to be in the range of approximately RMB 10.9 million to RMB 15.9 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT PHARMA Forecasts Net Loss Between RMB 10.9 Million and RMB 15.9 Million for 2025 Fiscal Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT PHARMA Forecasts Net Loss Between RMB 10.9 Million and RMB 15.9 Million for 2025 Fiscal Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NT PHARMA (01011) has announced that following further discussions with its auditor during the audit process and based on audit work completed to the date of this announcement, the Board wishes to further inform shareholders and potential investors that the Group expects to recognize a one-time non-cash gain of approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) related to the issuance of new shares for debt settlement. Consequently, the Group's anticipated loss for the fiscal year ending December 31, 2025, is expected to be reduced by approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) compared to the figure disclosed in the previous announcement. The revised expected net loss is now projected to be in the range of approximately RMB 10.9 million to RMB 15.9 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1152861261","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152861261","pubTimestamp":1774885895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"NT PHARMA (01011) has announced that following further discussions with its auditor during the audit process and based on audit work completed to the date of this announcement, the Board wishes to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01011":"泰凌医药"},"translate_title":"泰凌医药预计2025财年净亏损1090万元至1590万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"NT PHARMA (01011) has announced that following further discussions with its auditor during the audit process and based on audit work completed to the date of this announcement, the Board wishes to further inform shareholders and potential investors that the Group expects to recognize a one-time non-cash gain of approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) related to the issuance of new shares for debt settlement. Consequently, the Group's anticipated loss for the fiscal year ending December 31, 2025, is expected to be reduced by approximately HKD 15.4 million (equivalent to roughly RMB 14.1 million) compared to the figure disclosed in the previous announcement. The revised expected net loss is now projected to be in the range of approximately RMB 10.9 million to RMB 15.9 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}